Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

References

• Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials. and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014;275(3):251-83
   PubMed Web of Science ®Google Scholar
• Thies W, Bleiler L; Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 2013;9(2):208-45
   PubMed Web of Science ®Google Scholar
• Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. Curr Opin Neurobiol 2011;11(5):585-90
   Google Scholar
• Panza F, Logroscino G, Imbimbo BP, Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatry 2014;27(2):128-37
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):280-92
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):270-9
   PubMed Web of Science ®Google Scholar
• Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013;9(1):54-8
   PubMedGoogle Scholar
• Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367(9):795-804
   PubMed Web of Science ®Google Scholar
• Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12(4):357-67
   PubMed Web of Science ®Google Scholar
• Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-β-associated clinical decline occurs only in the presence of elevated Ptau. Arch Neurol 2012;69(6):709-13
   PubMedGoogle Scholar
• Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA–AA preclinical Alzheimer disease. Neurology 2012;78(20):1576-82
   PubMedGoogle Scholar
• Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to NIA–AA criteria for preclinical Alzheimer’s disease. Ann Neurol 2012;71(6):765-75
   PubMedGoogle Scholar
• Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 2013;73(4):472-80
   PubMedGoogle Scholar
• Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 2014;10(3):405-19
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rentz DM, Johnson KA, et al. The A4 Study: stopping AD before symptoms begin? Sci Transl Med 2014;6(228):228fs13
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company with Alzheimer’s disease cooperative study (ADCS). Clinical trial of solanezumab for older individuals who may be at risk for memory loss (A4). ClinicalTrials.gov NCT02008357 Available from: http://clinicaltrials.gov/ct2/show/NCT02008357?term=Anti-Amyloid+Treatment+in+Asymptomatic+AD&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Mills SM, Mallmann J, Santacruz AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013;169(10):737-43
   PubMed Web of Science ®Google Scholar
• Washington University School of Medicine with Eli Lilly and Company, Hoffmann-La Roche, Alzheimer’s Association, National Institute on Aging (NIA), and Avid Radiopharmaceuticals. Dominantly Inherited Alzheimer network trial: an opportunity to prevent dementia. A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation. (DIAN TU). ClinicalTrials.gov NCT01760005 Available from: http://clinicaltrials.gov/ct2/show/NCT01760005?term=NCT01760005&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(Suppl 3):321-9
   PubMed Web of Science ®Google Scholar
• Genentech and Banner Alzheimer’s Institute. A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer disease, including a placebo-treated noncarrier cohort. ClinicalTrials.gov NCT01998841 Available from: http://clinicaltrials.gov/ct2/show/NCT01998841?term=NCT01998841&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Lannfelt L, Relkin NR, Siemers ER. Amyloid-ß-directed immunotherapy for Alzheimer’s disease. J Intern Med 2014;275(3):284-95
   PubMed Web of Science ®Google Scholar
• Marciani DJ. New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today 2014; Epub ahead of print
   PubMedGoogle Scholar
• Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener 2013;8:36
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-19
   PubMed Web of Science ®Google Scholar
• Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis 2005;2(5):261-6
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Imbimbo BP, et al. Anti-β-amyloid immunotherapy for Alzheimer’s disease: focus on bapineuzumab. Curr Alzheimer Res 2011;8(8):808-17
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Rev Clin Immunol 2012;8(2):135-49
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Murray ED, Price BH, Tarazi FI. Bapineuzumab and solanezumab for Alzheimer’s disease: is the ’amyloid cascade hypothesis’ still alive? Expert Opin Biol Ther 2013;13(7):1075-84
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):322-33
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311-21
   PubMed Web of Science ®Google Scholar
• Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease - are we on the right road? N Engl J Med 2014;370(4):377-8
   PubMedGoogle Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9(4):363-72
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H, Rinne JO, et al. AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69(8):1002-10
   PubMedGoogle Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73(24):2061-70
   PubMed Web of Science ®Google Scholar
• Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7(4):367-85
   PubMed Web of Science ®Google Scholar
• Maia LF, Kaeser SA, Reichwald J, et al. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 2013;5(194):194re2
   PubMedGoogle Scholar
• Fagan AM, Xiong C, Jasielec MS, et al. Dominantly inherited Alzheimer network. longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 2014;6(226):226ra30
   PubMedGoogle Scholar
• Pfizer and JANSSEN Alzheimer immunotherapy research & development, LLC. Study evaluating the safety of AAB-003 (PF-05236812) in subjects with Alzheimer’s disease. ClinicalTrials.gov NCT01193608 Available from: http://clinicaltrials.gov/ct2/show/NCT01193608?term=NCT01193608&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Pfizer and JANSSEN Alzheimer immunotherapy research & development, LLC. Open label extension study evaluating safety and tolerability of AAB-003 (PF-05236812) in subject with mild to moderate Alzheimer’s disease. ClinicalTrials.gov NCT01369225 Available from: http://clinicaltrials.gov/ct2/show/NCT01369225?term=NCT01369225&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 2012;8(4):261-71
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33(2):67-73
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Continued safety monitoring of solanezumab in Alzheimer’s disease (EXPEDITION EXT). ClinicalTrials.gov NCT01127633 http://clinicaltrials.gov/ct2/show/NCT01127633?term=NCT00905372&rank=2 [Last accessed 10 June 2014]
   Google Scholar
• Eli Lilly and Company. Progress of mild Alzheimer’s disease in participants on solanezumab versus placebo (EXPEDITION3). ClinicalTrials.gov NCT01900665 Available from: http://clinicaltrials.gov/ct2/show/NCT01900665?term=NCT01900665&rank=1 [Last accessed 18 May 2014]
   Google Scholar
• Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer’s disease: what are the most promising targets? Immun Ageing 2013;10(1):18
   PubMed Web of Science ®Google Scholar
• Delrieu J, Ousset PJ, Vellas B. Gantenerumab for the treatment of Alzheimer’s disease. Expert Opin Biol Ther 2012;12(8):1077-86
   PubMed Web of Science ®Google Scholar
• Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Des Devel Ther 2013;7:1359-64
   PubMed Web of Science ®Google Scholar
• Lemere CA, Lopera F, Kosik KS, et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 1996;2(10):1146-50
   PubMed Web of Science ®Google Scholar
• Lopera F, Ardilla A, Martinez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277(10):793-9
   PubMed Web of Science ®Google Scholar
• Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer’s disease and the prospect of presymptomatic intervention. J Alzheimers Dis 2013;33(Suppl 1):S405-16
   PubMedGoogle Scholar
• Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuropotection and glial engulfment of Aβ. J Neurosci 2012;32(28):9677-89
   PubMed Web of Science ®Google Scholar
• Genentech. A study to evaluate the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer’s disease (ABBY). ClinicalTrials.gov NCT01343966 Available from: http://clinicaltrials.gov/ct2/show/NCT01343966?term=NCT01343966&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Genentech. A study to evaluate the impact of MABT5102A on brain amyloid load and related biomarkers in patients with mild to moderate Alzheimer’s disease. ClinicalTrials.gov NCT01397578 Available from: http://clinicaltrials.gov/ct2/show/NCT01397578?term=MABT5102A&rank=3 [Last accessed 10 June 2014]
   Google Scholar
• Genentech. A long-term safety extension study of studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer’s disease treated with crenezumab. ClinicalTrials.gov NCT01723826 Available from: http://clinicaltrials.gov/ct2/show/NCT01723826?term=NCT01723826&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Eisai Inc. A randomized, double-blind, placebo-controlled, combined single ascending dose and multiple ascending dose study. ClinicalTrials.gov identifier NCT01230853 Available from: http://clinicaltrials.gov/ct2/show/NCT01230853?term=NCT01230853&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Eisai Inc. A study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early Alzheimer’s disease. ClinicalTrials.gov identifier NCT01767311 Available from: http://clinicaltrials.gov/ct2/show/NCT01900665?term=NCT01900665&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer’s disease. Expert Opin Biol Ther 2011;11(3):343-57
   PubMed Web of Science ®Google Scholar
• Loeffler DA. Intraveneous immunoglobulin and Alzheimer’s disease: what now? J Neuroinflammation 2013;10(1):70
   PubMedGoogle Scholar
• Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75(10):1472-4
   PubMed Web of Science ®Google Scholar
• Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer’s disease. Neurology 2008;70:A393
   Google Scholar
• Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12(3):233-43
   PubMedGoogle Scholar
• Baxter Healthcare Corporation. A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild-to-moderate Alzheimer´s disease. ClinicalTrials.gov NCT00818662 Available from: http://clinicaltrials.gov/ct2/show/NCT00818662?term=NCT00818662&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Sutter Health. Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment (MCI). ClinicalTrials.gov NCT01300728 Available from: http://clinicaltrials.gov/ct2/show/NCT01300728?term=NCT01300728&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Instituto Grifols SA. A study to evaluate albumin and immunoglobulin in Alzheimer’s disease (AMBAR). ClinicalTrials.gov NCT01561053 Available from: http://clinicaltrials.gov/ct2/show/NCT01561053?term=NCT01561053&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Rauchenberger R, Borges E, Thomassen-Wolf E, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor3. J Biol Chem 2003;278(40):38194-205
   PubMedGoogle Scholar
• Steidl S, Ratsch O, Brocks B, et al. In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 2008;46(1):135-44
   PubMedGoogle Scholar
• Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrating sustained cerebral amyloid-b binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012;28(1):49-69
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69(2):198-207
   PubMedGoogle Scholar
• Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52
   PubMed Web of Science ®Google Scholar
• Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 2008;131(Pt 12):3299-310
   PubMedGoogle Scholar
• Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 2008;28(52):14156-64
   PubMedGoogle Scholar
• Seubert P, Khan K, Motter R, et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP Mouse. Neurodegener Dis 2008;5(2):65-71
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2001;98(15):8850-5
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche F. A study of a high concentration liquid formulation versus a lyophilized formulation of gantenerumab in healthy volunteers. ClinicalTrials.gov NCT01636531 Available from: http://clinicaltrials.gov/ct2/show/NCT01636531?term=gantenerumab&rank=5 [Last accessed 10 June 2014]
   Google Scholar
• Chugai Pharmaceutical. A multiple-dose study of gantenerumab in Japanese Alzheimer’s disease patients. ClinicalTrials.gov NCT01656525 Available from: http://clinicaltrials.gov/ct2/show/NCT01656525?term=gantenerumab&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Hoffmann-La Roche F. A study investigating the bioavailability of a high concentration liquid formulation versus a reference lyophilized formulation of gantenerumab in healthy volunteers. ClinicalTrials.gov NCT02133937 Available from: http://clinicaltrials.gov/ct2/show/NCT02133937?term=gantenerumab&rank=2 [Last accessed 10 June 2014]
   Google Scholar
• Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-92
   PubMed Web of Science ®Google Scholar
• Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5(5):48
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche F. A study of gantenerumab in patients with prodromal Alzheimer’s disease. ClinicalTrials.gov NCT01224106 Available from: http://clinicaltrials.gov/ct2/show/NCT01224106?term=NCT01224106&rank=1 [Last accessed 10 June 2014]
   Google Scholar
• Hoffmann-La Roche F. A study of gantenerumab in patients with mild Alzheimer disease. ClinicalTrials.gov NCT02051608 Available from: http://clinicaltrials.gov/ct2/show/NCT02051608?term=gantenerumab&rank=3 [Last accessed 10 June 2014]
   Google Scholar
• Weller RO, Subash M, Preston SD, et al. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 2008;18(2):253-66
   PubMedGoogle Scholar
• Racke MM, Hepburn DL, Parsadainian M, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25(3):629-36
   PubMedGoogle Scholar
• Das P, Loosbrock N, Dickson D, et al. Amyloid-(beta) immunization effectively reduces amyloid deposition in Fcr(gamma)(-/-) knock-out mice. J Neurosci 2003;23(24):8532-8
   PubMed Web of Science ®Google Scholar
• Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol 2009;118(1):87-102
   PubMedGoogle Scholar
• Giuffrida ML, Caraci F, Pignataro B, et al. Beta-amyloid monomers are neuroprotective. J Neurosci 2009;29(34):10582-7
   PubMed Web of Science ®Google Scholar